708P PD-L1 as a predictor of survival in patients with metastatic urothelial carcinoma (mUC) from the phase III DANUBE trial of durvalumab (D) or durvalumab plus tremelimumab (D+T) versus standard of care chemotherapy (SoC)Joaquim Bellmunt, Sophie Wildsmith, Michiel S. van der Heijden et al.|Annals of Oncology|2021Cited by 2